April 11, 2017 / 11:17 AM / 3 months ago

BRIEF-Bristol-Myers and Apexigen announce clinical collaboration to evaluate Opdivo in combination with APX005M in advanced solid tumors

1 Min Read

April 11 (Reuters) - Bristol-myers Squibb Co

* Bristol-Myers Squibb and Apexigen, Inc. announce clinical collaboration to evaluate Opdivo (nivolumab) in combination with APX005M in advanced solid tumors

* Bristol-Myers - Study to evaluate potential of APX005M + Opdivo to activate antigen-presenting cells in tumor microenvironment to show anti-tumor activity

* Bristol-Myers Squibb- Study to enroll second-line metastatic non-small cell lung cancer patients who have failed prior chemotherapy

* Study to also enroll metastatic melanoma patients who have failed prior I-O therapy Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below